Company to Pursue Technologies to Improve Muscle Strength, Bone Health, and Other Longevity Indicators
NEW YORK, July 24, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO)...
Early data from robust Autonomy Phase 2b posdinemab trial demonstrate Company's leadership in multimodal biomarkers and early detection
New findings highlight the central role of...
CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 2025 Alzheimer’s Association International Conference (AAIC), taking place July 27-31 in Toronto, Canada. Data on LEQEMBI® (lecanemab) will include 48-month results from the Clarity AD open-label extension, real-world evidence, and new insights into a subcutaneous formulation for maintenance dosing. Presentations on tau will explore tau-targeted therapies and biomarkers, including baseline characteristics of participants from CELIA, a Phase 2 trial evaluating the efficacy, safety, and tolerability of BIIB080, an investigational antisense oligonucleotide (ASO) therapy that targets tau.